<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00690092</url>
  </required_header>
  <id_info>
    <org_study_id>S104-1, S104-2, S104-3</org_study_id>
    <nct_id>NCT00690092</nct_id>
  </id_info>
  <brief_title>A Multi-center Study of Spherule-Derived Coccidioidin</brief_title>
  <official_title>Safety, Sensitivity and Specificity of Spherule-derived Coccidioidin in Naive Adults, in Adults With a History of Pulmonary Coccidioidomycosis and in Adults With a History of Pulmonary Histoplasmosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nielsen BioSciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sr Consultants Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nielsen BioSciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adult volunteers were skin tested with 1.27 ug spherule-derived coccidioidin. The skin test
      antigen was evaluated in three different populations of adult volunteers to determine the
      safety and efficacy of the product in the assessment of delayed-type hypersensitivity to
      Coccidioides immitis. Induration greater than or equal to 5 mm after 48 hours was considered
      positive for exposure to C. immitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the ability of spherule-derived coccidioidin to detect cellular hypersensitivity to C. immitis by a positive DTH skin test in a population with a history of pulmonary coccidioidomycosis.</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the specificity of spherule-derived coccidioidin by testing the skin test antigen in naive adult volunteer and volunteers with a history of pulmonary histoplasmosis.</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Coccidioidomycosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volunteers with a history of pulmonary coccidioidomycosis verified by serology and/or histology or mycology.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volunteers without a history of pulmonary coccidioidomycosis confirmed by serology (naive).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volunteers with a history of pulmonary histoplasmosis but no history of coccidioidomycosis confirmed by serology.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Spherule-derived coccidioidin</intervention_name>
    <description>1.27 ug of sterile, injectable product (spherule-derived coccidioidin). Product was administered once by intradermal injection along with positive and negative control agents and results read after 48 hours.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Coccidioidin SD (proposed trade name)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good Health (absence of active medical disease)

          -  Meets criteria specific to population groups:

               -  Coccidioidomycosis Group:

          -  History of coccidioidomycosis of at least 45 days duration confirmed by roentgenograph
             serologic or mycologic findings

               -  Histoplasmosis Group:

          -  History of pulmonary histoplasmosis

               -  Naive Control Group:

          -  Lifetime residence in the states of WA, OR, ID, or MT

          -  Never employed as an agricultural worker

          -  Serology negative for C.immitis antibodies

        Exclusion Criteria (All Groups):

          -  Active medical disease

          -  Alcohol abuse or illicit drug use

          -  Influenza-like illness within the past 4 weeks

          -  Immunizations within the past 4 weeks

          -  Current atopic or contact dermatitis, psoriasis, erythema nodosum, urticaria

          -  Current treatment with corticosteroids, cytotoxic or immunosuppressive drugs

          -  Immunodeficiency disease

          -  HIV infection

          -  Previous skin test with coccidioidin or SD Coccidioidin

          -  Pregnant or lactating

          -  Adverse reaction to thimerosal

          -  Adverse reaction to Candida or Trichophyton skin test antigens

        Coccidioidomycosis Group:

          -  Current cavitary or disseminated coccidioidomycosis

          -  History of histoplasmosis, or blastomycosis

        Histoplasmosis Group:

          -  History of coccidioidomycosis or blastomycosis

        Naive Control Group:

          -  History of coccidioidomycosis, histoplasmosis, blastomycosis

          -  Travel for more than 30 days in designated areas of CA, AZ, NV, UT, NM, TX and Mexico,
             Central and South America. Travel for more than 7 days in restricted areas of CA, AZ
             and TX.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry S Nielsen, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Nielsen BioSciences, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Royce Johnson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kern Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neil Ampel, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona, Tucson</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brad Sawtelle, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blair, NE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Kernerman, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spokane, WA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Health Sciences Center AVAHCS, Univ. of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kern Facility Medical Group</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blair Clinic</name>
      <address>
        <city>Blair</city>
        <state>Nebraska</state>
        <zip>68001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spokane Allergy and Asthma Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2008</study_first_submitted>
  <study_first_submitted_qc>June 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2008</study_first_posted>
  <last_update_submitted>October 28, 2013</last_update_submitted>
  <last_update_submitted_qc>October 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2013</last_update_posted>
  <responsible_party>
    <name_title>Harry S. Nielsen, Ph.D.</name_title>
    <organization>Allermed Laboratories, Inc.</organization>
  </responsible_party>
  <keyword>Coccidioidin</keyword>
  <keyword>Coccidioidin SD</keyword>
  <keyword>Spherule-derived coccidioidin</keyword>
  <keyword>Coccidioidomycosis</keyword>
  <keyword>Valley Fever</keyword>
  <keyword>Coccidioides immitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coccidioidomycosis</mesh_term>
    <mesh_term>Coccidiosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

